Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients
Four years after the European Commission sanctioned the use of Celgene’s flagship Revlimid to treat adults with previously-untreated multiple myeloma who are not eligible for transplant, England’s National Health Service (NHS) will adopt its use as the first or second line of defense — in certain patients. Although the blockbuster drug is routinely used as a backbone treatment in much of the developed world, until now, the drug was only cleared for third-line use by NICE.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.